Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$239.26 USD

239.26
644,194

0.00 (0.00%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $239.18 -0.08 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (46 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

NextGen's New Platform Set to Improve Patient Engagement

by Zacks Equity Research

The availability of NextGen's (NXGN) Patient Experience Platform is likely to enable high-quality healthcare and drive patient engagement.

Zacks Equity Research

Buy These 5 Low Leverage Stocks Amid Coronavirus Outbreak

by Zacks Equity Research

Higher debt financing is never desirable. So, an investor's portfolio should include stocks that are not highly leveraged.

Zacks Equity Research

Here's Why You Should Hold on to CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.

Zacks Equity Research

Masimo Inks Deal With Imprivata, Improves Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) partnership with Imprivata is likely to boost patient outcomes through the integration of Imprivata Medical Device Access into Masimo's Hospital Automation solutions.

Zacks Equity Research

Here's Why You Should Retain HMS Holdings (HMSY) Stock Now

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services.

Zacks Equity Research

Here's Why You Should Invest in Intuitive Surgical Stock Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, stiff competition remains a woe.

Zacks Equity Research

Here's Why You Should Hold on to OPKO Health Stock for Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

Zacks Equity Research

Here's Why You Should Invest in Integer Holdings Stock Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

Zacks Equity Research

MCK or WST: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MCK vs. WST: Which Stock Is the Better Value Option?

Zacks Equity Research

STERIS' (STE) Growth Picture Impressive Amid Rising Costs

by Zacks Equity Research

STERIS (STE) growing steadily on favorable underlying market trends, along with new product and service offerings.

Zacks Equity Research

Integra LifeSciences Grows Organically Amid Supply Issues

by Zacks Equity Research

Integra LifeSciences' (IART) Codman Specialty Surgical segment registers impressive organic growth in Q4.

Zacks Equity Research

Integer Holdings Acquires Inomec, Extends Global Foothold

by Zacks Equity Research

Integer Holdings' (ITGR) Inomec buyout is likely to boost R&D pipeline and also strengthen and expand global foothold.

Zacks Equity Research

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.

Zacks Equity Research

Here's Why You Should Invest in Cardinal Health Stock Now

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.

Urmimala Biswas headshot

Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More

by Urmimala Biswas

Strong foothold in the emerging markets so far widely contributes to some of the industry players' Q4 results.

Zacks Equity Research

Analysts Estimate West Pharmaceutical Services (WST) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Retain IDEXX Laboratories Stock Now

by Zacks Equity Research

Investor confidence remains high in IDEXX (IDXX) stock, thanks to solid prospects.

Zacks Equity Research

Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Quest Diagnostics (DGX) gains from several positive developments like partnerships and acquisitions.

Zacks Equity Research

Quest Diagnostics to Buy Select Assets of Memorial Hermann

by Zacks Equity Research

The acquisition is a step forward in Quest Diagnostics' (DGX) commitment toward offering high-quality, cost-efficient diagnostic services in Texas,especially the Houston metropolitan area.

Zacks Equity Research

PDCO vs. WST: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PDCO vs. WST: Which Stock Is the Better Value Option?

Zacks Equity Research

Masimo Posts Solid Preliminary 2019 Results, Issues Guidance

by Zacks Equity Research

Higher revenues and upbeat 2020 outlook benefit Masimo's (MASI) preliminary full-year 2019 results.

Zacks Equity Research

Here's Why You Should Add Bruker (BRKR) to Your Portfolio Now

by Zacks Equity Research

Investor confidence in Bruker (BRKR) is at a high, thanks to solid prospects.

Trina Mukherjee headshot

5 Promising Growth Stocks in MedTech to Invest in 2020

by Trina Mukherjee

We have zeroed in on five impressive growth stocks in MedTech on the back of the industry's lucrative prospects.

Zacks Equity Research

Baxter Posts Upbeat Q4 Preliminary Results, Issues Guidance

by Zacks Equity Research

Higher revenues, growth in all geographic segments and six business units benefit Baxter's (BAX) Q4 preliminary operating results.

Zacks Equity Research

Here's Why You Should Hold on to Cardinal Health Stock Now

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.